ImmunoGen Announces Conference Call to Discuss Its First Quarter 2017 Financial Results

(Nasdaq: IMGN), a leader in the expanding field of
antibody-drug conjugates (ADCs) for the treatment of cancer, today
announced that the Company will host a conference call at 8:00 a.m. ET
on Friday, May 5, 2017 to discuss its first quarter 2017 financial
results. Management will also provide a brief update on the business.

To access the live call by phone, dial 719-325-2452; the conference ID
is 5957421. The call may also be accessed through the Investors section
of the Company’s website,
Following the live webcast, a replay of the call will be available at
the same location through May 19, 2017.

About ImmunoGen, Inc.

ImmunoGen is a clinical-stage biotechnology company that develops
targeted cancer therapeutics using its proprietary ADC technology.
ImmunoGen’s lead product candidate, mirvetuximab soravtansine, is in a
Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is
in Phase 1b/2 testing in combination regimens for earlier-stage disease.
ImmunoGen’s ADC technology is used in Roche’s marketed product, Kadcyla®,
in three other clinical-stage ImmunoGen product candidates, and in
programs in development by partners Amgen, Bayer, Biotest, CytomX,
Lilly, Novartis, Sanofi and Takeda. More information about the Company
can be found at

Kadcyla® is a registered trademark of Genentech, a member of
the Roche Group.


For Investors
Thrust IR
Monique Allaire, 617-895-9511

FTI Consulting, Inc.
Robert Stanislaro, 212-850-5657